Patents by Inventor Matthias Grell
Matthias Grell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8410143Abstract: The present invention relates to methylene urea derivatives of formula (I), the use of the compounds of formula (I) as inhibitors of raf-kinase, the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.Type: GrantFiled: June 19, 2009Date of Patent: April 2, 2013Assignee: Merck Patent GmbHInventors: Hans-Peter Buchstaller, Matthias Wiesner, Oliver Schadt, Christiane Amendt, Frank Zenke, Christian Sirrenberg, Matthias Grell, Dirk Finsinger
-
Patent number: 8158799Abstract: Compounds of the formula I in which X, Y, R1, R1?, R2, R3 have the meanings indicated in Claim 1, are inhibitors of cell proliferation and can be employed for the treatment of tumors.Type: GrantFiled: November 14, 2006Date of Patent: April 17, 2012Assignee: Merck Patent Gesellschaft MIT Meschraenkter HaftungInventors: Oliver Schadt, Dieter Dorsch, Claus Fittschen, Matthias Grell
-
Publication number: 20110177027Abstract: The invention relates to a combination therapy for the treatment of tumors metastases comprising administration of anti-angiogenic agents and tumor necrosis factor alpha (TNFa) optionally together with other cytotoxic agents, such as interferon gamma (IFNy) or chemotherapeutic agents such as anti-EGFR antibodies. The method and the pharmaceutical compositions comprising said agents can result in a synergistic potentiation of the tumor cell proliferation inhibition effect of each individual therapeutic agent, yielding more effective treatment than found by administering an individual component alone.Type: ApplicationFiled: March 21, 2011Publication date: July 21, 2011Inventors: Matthias GRELL, Simon GOODMAN, Curzio RUEGG
-
Publication number: 20110165150Abstract: The invention relates to a combination therapy for the treatment of tumors and tumor metastases comprising administration of integrin ligands, preferably integrin antagonists, together with co-therapeutic agents or therapy forms that have synergistic efficacy when administered together with said ligands, such as chemotherapeutic agents and/or radiation therapy, in isolated organ perfusion. The therapy results in a synergistic potential increase of the inhibition effect of each individual therapeutic on tumor cell proliferation, yielding more effective treatment than found by administering an individual component alone.Type: ApplicationFiled: January 18, 2006Publication date: July 7, 2011Applicant: Merck Patent GmbHInventors: Simon Goodman, Matthias Grell, Timo L.M. Ten Hagen, Alexander M.M. Eggermont
-
Patent number: 7691870Abstract: The present invention relates to benzimidazole carboxamides of formula I, the use of the compounds of formula I of as inhibitors of one or more kinases, the use of the compounds of formula I for the manufacture of pharmaceutical compositions and methods of treatment, comprising administering said pharmaceutical compositions to a patients.Type: GrantFiled: June 11, 2004Date of Patent: April 6, 2010Assignee: Merck Patent GmbHInventors: Hans-Peter Buchstaller, Matthias Wiesner, Frank Zenke, Christiane Amendt, Matthias Grell, Christian Sirrenberg
-
Patent number: 7691886Abstract: The present invention relates to benzimidazole derivatives of formula I, the use of the compounds of formula I as inhibitors of one or more kinases, the use of the compounds of formula I for the manufacture of a pharmaceutical compositions and methods of treatment, comprising administering said pharmaceutical compositions to patients.Type: GrantFiled: June 15, 2004Date of Patent: April 6, 2010Assignee: Merck Patent GmbHInventors: Hans-Peter Buchstaller, Dirk Finsinger, Matthias Wiesner, Lars Thore Burgdorf, Christiane Amendt, Matthias Grell, Christian Sirrenberg, Frank Zenke
-
Publication number: 20090298885Abstract: The present invention relates to methylene urea derivatives of formula (I), the use of the compounds of formula (I) as inhibitors of raf-kinase, the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.Type: ApplicationFiled: June 19, 2009Publication date: December 3, 2009Applicant: Merck Patent GmbHInventors: Hans-Peter Buchstaller, Matthias Wiesner, Oliver Schadt, Christiane Amendt, Frank Zenke, Christian Sirrenberg, Matthias Grell, Dirk Finsinger
-
Publication number: 20090253688Abstract: The present invention relates to semicarbazide derivatives of formula I, the use of the compounds of formula I as inhibitors of one or more kinases, the use of the compounds of formula I for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.Type: ApplicationFiled: February 14, 2005Publication date: October 8, 2009Applicant: Merck Patent GmbHInventors: Hans-Peter Buchstaller, Dirk Finsinger, Frank Stieber, Matthias Wiesner, Christiane Amendt, Christian Sirrenberg, Frank Zenke, Matthias Grell
-
Patent number: 7598274Abstract: Compounds of the formula (I), in which X, Y, Z and Ar have the meanings indicated in claim 1, are inhibitors of Raf kinase and can be employed, inter alia, for the treatment of tumoursType: GrantFiled: October 26, 2004Date of Patent: October 6, 2009Assignee: Merck Patent GmbHInventors: Dirk Finsinger, Hans-Peter Buchstaller, Lars Burgdorf, Matthias Wiesner, Christiane Amendt, Matthias Grell, Christian Sirrenberg, Frank Zenke
-
Patent number: 7589112Abstract: The present invention relates to methylene urea derivatives of formula (I), the use of the compounds of formula (I) as inhibitors of raf-kinase, the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.Type: GrantFiled: October 8, 2003Date of Patent: September 15, 2009Assignee: Merck Patent GmbHInventors: Hans-Peter Buchstaller, Matthias Wiesner, Oliver Schadt, Christiane Amendt, Frank Zenke, Christian Sirrenberg, Matthias Grell, Dirk Finsinger
-
Publication number: 20090163556Abstract: The present invention relates to glycinamide derivatives of formula I, A-D-B??(I), wherein A, D, and B are as herein defined, as well as the use of the compounds of formula I as inhibitors of raf-kinase, the use of the compounds of formula I for the manufacture of a pharmaceutical composition, and a method of treatment comprising administering said pharmaceutical composition to a patient.Type: ApplicationFiled: November 18, 2008Publication date: June 25, 2009Inventors: Hans-Peter Buchstaller, Matthias Wiesner, Oliver Schadt, Christiane Amendt, Frank Zenke, Christian Sirrenberg, Matthias Grell
-
Publication number: 20090130098Abstract: The invention relates to a combination therapy for the treatment of tumors and tumor metastases comprising administration of integrin ligands, preferably integrin antagonists, together with co-therapeutic agents or therapy forms that have synergistic efficacy when administered consecutively with said ligands, such as chemotherapeutic agents and or radiation therapy. The therapy results in a synergistic potential increase of the inhibition effect of each individual therapeutic on tumor cell proliferation, yielding more effective treatment than found by administering an individual component alone, concurrently or not in the dosage regime of the present invention.Type: ApplicationFiled: January 18, 2007Publication date: May 21, 2009Applicant: Merck Patent GmbHInventors: Simon Goodman, Martin Andreas Picard, Tom Mikkelsen, Johannes Nippgen, Ulrike Grimm, Roger Stupp, Michael Weller, Andreas Harstrick, Matthias Grell
-
Publication number: 20090035270Abstract: The invention relates to a combination therapy for the treatment of tumors metastases comprising administration of anti-angiogenic agents and rumor necrosis factor alpha (TNFa) optionally together with other cytotoxic agents, such as interferon gamma (IFNy) or chemotherapeutic agents such as anti-EGFR antibodies. The method and the pharmaceutical compositions comprising said agents can result in a synergistic potentiation of the tumor cell proliferation inhibition effect of each individual therapeutic agent, yielding more effective treatment than found by administering an individual component alone.Type: ApplicationFiled: September 4, 2007Publication date: February 5, 2009Inventors: Matthias Grell, Simon Goodman, Curzio Ruegg
-
Patent number: 7476683Abstract: The present invention relates to glycinamide derivatives of formula (I), the use of the compounds of formula (I) as inhibitors of raf-kinase, the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.Type: GrantFiled: July 31, 2003Date of Patent: January 13, 2009Assignee: Merck Patent GmbHInventors: Hans-Peter Buchstaller, Matthias Wiesner, Oliver Schadt, Christiane Amendt, Frank Zenke, Christian Sirrenberg, Matthias Grell
-
Publication number: 20080312278Abstract: Compounds of the formula I in which X, Y, R1, R1?, R2, R3 have the meanings indicated in claim 1, are inhibitors of cell proliferation and can be employed for the treatment of tumours.Type: ApplicationFiled: November 14, 2006Publication date: December 18, 2008Inventors: Oliver Schadt, Dieter Dorsch, Claus Fittschen, Matthias Grell
-
Patent number: 7368295Abstract: The present invention relates to nanoparticles with tumor necrosis factor (TNF) or cytokine immobilized thereon, where TNF or the cytokine is preferably immobilized in the form of a trimer in directed fashion and with retention of its biological activity on the carrier, to methods for the directed immobilization of TNF or cytokine on nanoparticles, to the use of the nanoparticles having immobilized TNF or cytokine for the identification and/or isolation of cytokine- or TNF-binding partners and for the identification and/or isolation of inhibitors of the interaction between TNF or cytokine and its binding partners, to the use of such nanoparticles for preparing a pharmaceutical composition, in particular for the therapy of tumors, and to pharmaceutical and diagnostic compositions which comprise such nanoparticles.Type: GrantFiled: August 16, 2002Date of Patent: May 6, 2008Assignee: Fraunhofer-Gesellschaft zur Foderung der Angewandten Forschung E.V.Inventors: Günter Tovar, Thomas Schiestel, Herwig Brunner, Klaus Pfizenmaier, Matthias Grell, Peter Scheurich, Angela Hammer
-
Publication number: 20070213374Abstract: The present invention relates to malonamide derivatives of formula A-D-B-1, as inhibitors of raf-kinase and the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition.Type: ApplicationFiled: June 18, 2004Publication date: September 13, 2007Applicant: Merck Patent GmbHInventors: David Bruge, Hans-Peter Buchstaller, Matthias Wiesner, Dirk Finsinger, Manfred Baumgarth, Christian Sirrenberg, Frank Zenke, Christian Amendt, Matthias Grell
-
Publication number: 20070191423Abstract: The present invention relates to isoquinoline derivatives of formula (I), the use of the compounds of formula (I), as inhibitors of one or more kinases, the use of the compounds of formula (I), for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.Type: ApplicationFiled: February 1, 2005Publication date: August 16, 2007Applicant: Merck Patent GmbHInventors: Hans-Peter Buchstaller, Lars Burgdorf, Dirk Finsinger, Christiana Amendt, Matthias Grell, Christian Sirrenberg, Frank Zenke
-
Publication number: 20070191353Abstract: Use of compounds of the formula (I), in which Ar1, Ar2 and Z have the meanings indicated in Patent Claim 1, for the prophylaxis and/or treatment of diseases in which the inhibition, regulation and/or modulation of signal transduction by kinases, in particular RAF kinases, plays a role.Type: ApplicationFiled: January 31, 2005Publication date: August 16, 2007Inventors: Lars Burgdorf, Frank Stieber, Hans-Peter Buchstaller, Soheila Anzali, Christiane Amendt, Hartmut Greiner, Matthias Grell, Christian Sirrenberg, Frank Zenke
-
Publication number: 20070191444Abstract: The present invention relates to benzimidazolyl derivatives of formula (I), with the definition of R8, p, Ar1, E, D, R9, q and R10 according to claim 1, the use of the compounds of formula (I) as inhibitors of one or more kinases, the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.Type: ApplicationFiled: February 14, 2005Publication date: August 16, 2007Inventors: Hans-Peter Buchstaller, Lars Burgdorf, Frank Stieber, Christiane Amendt, Matthias Grell, Christian Sirrenberg, Frank Zenke